Vericiguat's Effects on Acute Coronary Syndrome Patients with Diminished Ejection Fraction: Insights from the EVE-ACSrEF Trial

1

The EVE-ACSrEF trial investigates vericiguat's efficacy in patients with acute coronary syndrome and heart failure with reduced ejection fraction.
2

Vericiguat is a soluble guanylate cyclase stimulator that enhances the NO-sGC-cGMP signaling pathway, potentially improving cardiac function.
3

The study enrolled 149 patients with ACS and HFrEF, comparing outcomes between those receiving vericiguat plus guideline-directed medical therapy and those receiving standard therapy.
4

Primary endpoints include cardiovascular death and hospitalization for heart failure, with secondary endpoints focusing on changes in left ventricular ejection fraction.
5

The trial aims to determine if adding vericiguat to existing treatments can reduce cardiovascular risks and improve quality of life for these patients.

1